Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Therapeutic Solutions Internat - SIC # 3843 - DENTAL EQUIPMENT AND SUPPLIES
Ticker
Exchange
SIC #
Website
Latest Ticker
TSOI
Over the counter
3843
https://therapeuticsolutionsint.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Therapeutic Solutions Internat
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
- Mar 4th, 2024 2:00 pm
Therapeutic Solutions International Announces Landmark Finding Regarding Mechanism of Action of its JadiCell Stem Cell Product
- Feb 29th, 2024 2:00 pm
Therapeutic Solutions International Files Patent on "Facilitating Effects" of JadiCells on Gene Therapy Mediated Cell Differentiation
- Feb 26th, 2024 2:00 pm
Therapeutic Solutions International Files Lawsuit in San Diego Superior Court to Obtain Identities of Certain Individuals or Entities
- Jan 22nd, 2024 7:58 pm
Therapeutic Solutions International Launches Adult Stem Cell Therapy Company Focused on Curing Epilepsy
- Jan 16th, 2024 2:00 pm
Therapeutic Solutions International Subsidiary Immunotherapy Company Res Nova Bio, Inc. Announces Positive Data on First Four Advanced Cancer Patients Treated with FloraStilbene™
- Jan 3rd, 2024 2:00 pm
Therapeutic Solutions International Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease
- Dec 11th, 2023 2:00 pm
Therapeutic Solutions International and Campbell Neurosciences Publish on Nutritional Modulation of the Indolamine 2,3 Dioxygenase Pathway as a Non-Toxic Means of Addressing Depression
- Nov 27th, 2023 2:00 pm
Therapeutic Solutions International Collaborates on Peer-Reviewed Publication on Personalized Immunotherapy for Brain Cancer Using mRNA
- Nov 20th, 2023 2:00 pm
Res Nova Biologics Announces First Cancer Patient Treated with FloraStilbene™
- Oct 20th, 2023 1:00 pm
Res Nova Biologics Recruits Abortion Pill Reversal Founder to Scientific Advisory Board
- Oct 17th, 2023 1:00 pm
Therapeutic Solutions International Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils
- Sep 29th, 2023 1:00 pm
Therapeutic Solutions International Recruits Internationally Renowned Stem Cell Clinician and San Diego Top Doctor to Scientific Advisory Board
- Sep 18th, 2023 1:00 pm
Therapeutic Solutions International Subsidiary Discloses Potential Solution to Immunotherapy Resistance in Cancer by "Healing Tumor" Before Killing It
- Sep 15th, 2023 1:00 pm
Therapeutic Solutions International Reports Landmark Advancement in Stem Cell Therapy of Frontotemporal Dementia
- Sep 11th, 2023 1:00 pm
FloraStilbene™ Demonstrates Synergy with Conventional Chemotherapy and Immunotherapy in Reducing Triple Negative Breast Cancer
- Aug 21st, 2023 1:30 pm
Therapeutic Solutions International Subsidiary Allogen Biologics Inc. Successfully Manufactures JadiCell Master Cell Bank to Provide Cells for Right to Try Use and Phase III ARDS Clinical Trial
- Aug 16th, 2023 12:39 pm
Therapeutic Solutions International Prevention Subsidiary Campbell Neurosciences Receives Notice of Allowance on Suicide Prevention Drug Candidate
- Jul 31st, 2023 1:00 pm
Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™
- Jul 18th, 2023 1:00 pm
Therapeutic Solutions International Files for Orphan Drug Designation Use of JadiCell Adult Stem Cells for Treatment of Frontotemporal Dementia
- Jul 12th, 2023 1:00 pm
Scroll